Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experienceSophie Park, François Dreyfus, Françoise Picard et al.|Blood|2007Cited by 332
Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomideCharikleia Kelaïdi, Pierre Fenaux, Sophie Park et al.|Leukemia Research|2008Cited by 78